Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

darifenacin

Known as: darifenacin [Chemical/Ingredient], darifenacine, Darifenacina 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
UNLABELLED Study Type--Therapy (prevalence) Level of Evidence 2b. What's known on the subject? and What does the study add… Expand
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2007
Highly Cited
2007
ABSTRACT Background: Overactive bladder (OAB) increases in prevalence with advancing age. This study specifically investigated… Expand
Is this relevant?
Highly Cited
2007
Highly Cited
2007
OBJECTIVE Previous studies have revealed that intravesical and systemic administration of oxybutinin suppress pelvic afferent… Expand
Is this relevant?
Highly Cited
2006
Highly Cited
2006
OBJECTIVES To investigate the effects of darifenacin controlled-release (CR) and oxybutynin extended-release (ER) on cognitive… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Review
2006
Review
2006
Muscarinic receptor antagonists (antimuscarinics) serve as the cornerstone in the pharmacological management of overactive… Expand
Is this relevant?
Highly Cited
2005
Highly Cited
2005
PURPOSE Overactive bladder is common in the elderly population, which is susceptible to cognitive disorders and drug induced… Expand
Is this relevant?
Highly Cited
2005
Highly Cited
2005
OBJECTIVES To evaluate the efficacy, tolerability and safety of a flexible-dosing strategy with darifenacin, an M(3)-selective… Expand
Is this relevant?
Highly Cited
2005
Highly Cited
2005
OBJECTIVE To evaluate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA… Expand
Is this relevant?
Highly Cited
2005
Highly Cited
2005
A randomized, double-blind, placebo-controlled, four-way crossover, safety study of darifenacin versus oxybutynin was carried out… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
Is this relevant?
Review
2004
Review
2004
OBJECTIVES To evaluate the efficacy, tolerability and safety of darifenacin, a once-daily M3) selective receptor antagonist (M3… Expand
Is this relevant?